StreetInsider.com News Articles

Xilio doses first patient in XTX501 lung cancer trial

Mon, 26 Oct 2026 07:30:38 -0400

Xilio Therapeutics, Inc. (Nasdaq: XLO) announced that the first patient has been dosed in a Phase 1/2 clinical trial evaluating XTX501, a PD-1/masked IL-2 bispecific antibody fusion protein, in patients with metastatic non-small cell lung cancer (NSCLC) who have previously received anti-PD(L)-1 therapy.

The first-in-human, multi-center, open-label trial is enrolling patients at multiple sites in the United States. The trial is initially evaluating the safety and tolerability of XTX501 as a monotherapy in patients with metastatic NSCLC and select advanced solid tumors. Xilio said it anticipates reporting initial Phase 1 data in the fourth quarter of 2027.

XTX501 combines inhibition of the

Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC

Mon, 26 Oct 2026 07:30:00 -0400

XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors

Anticipate reporting initial Phase 1 data in the fourth quarter of 2027

Plan to present a trial-in-progress poster for XTX501 at the Society for Immunotherapy of Cancer (SITC) 41^st Annual Meeting

WALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that the first patient has been dosed in its Phase

Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC

Mon, 26 Oct 2026 07:30:00 -0400

XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors

Anticipate reporting initial Phase 1 data in the fourth quarter of 2027

Plan to present a trial-in-progress poster for XTX501 at the Society for Immunotherapy of Cancer (SITC) 41^st Annual Meeting

Raymond James Starts Xilio Therapeutics Inc (XLO) at Outperform

Wed, 21 Oct 2026 06:05:41 -0400

Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics Inc (NASDAQ: XLO) with a Outperform rating and a price target of $16.00.

The analyst comments "We are initiating coverage of Xilio Therapeutics (XLO) with an Outperform rating and a price target of $16. Our thesis is predicated on three key points: 1) Xilio has administered its masking technology in multiple clinical programs with manageable safety and tolerability, 2) Xilio can leverage its current financial outlook to transition from legacy programs into modalities with a higher likelihood of success, namely masked T-cell engagers (TCEs), and 3) collaborations with pharma provide a

Raymond James Starts Xilio Therapeutics Inc (XLO) at Outperform

Wed, 21 Oct 2026 06:05:41 -0400

Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics Inc (NASDAQ: XLO) with a Outperform rating and a price target of $16.00.

Form 4 Xilio Therapeutics, Inc. For: Oct 01 Filed by: Houvras Yariv

Fri, 02 Oct 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20261002/27142907.html

Form 3 Xilio Therapeutics, Inc. For: Sep 28 Filed by: Houvras Yariv

Fri, 02 Oct 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20261002/27142876.html

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:30:00 -0400

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:30:00 -0400

Xilio Therapeutics names new chief medical officer

Mon, 28 Sep 2026 07:30:16 -0400

Xilio Therapeutics, Inc. (Nasdaq: XLO) has appointed Yariv J. Houvras, M.D., Ph.D. as chief medical officer, the clinical-stage biotechnology company announced Sept. 28, 2026.

Dr. Houvras brings more than 20 years of experience in clinical development, translational medicine, and immuno-oncology. He most recently served as senior vice president of clinical and translational development at Tubulis GmbH, where he oversaw antibody-drug conjugate programs in solid tumors and led multiple first-in-human and registration-enabling clinical studies. Tubulis was subsequently acquired by Gilead Sciences, Inc.

Before Tubulis, Dr. Houvras was senior medical director of hematology and translational sciences at Regeneron Pharmaceuticals, Inc., where he served as

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

Mon, 28 Sep 2026 07:30:00 -0400

Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology

WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Dr. Yariv Houvras as chief medical officer.

“We are thrilled to welcome Yariv at this exciting time for Xilio as we advance XTX501, our bispecific PD-1 / masked IL-2, in the clinic and our next generation of multi-specific, masked T

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

Mon, 28 Sep 2026 07:30:00 -0400

Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology

“We are thrilled to welcome Yariv at this exciting time for Xilio as we advance XTX501, our bispecific PD-1 / masked IL-2, in the clinic and our next generation of multi-specific, masked T

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:30:00 -0400

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

The stock options have an exercise price of $8.88 per share, which is equal to the closing price of the company’s common stock on September 1, 2026. Each stock option has a ten-year term

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:30:00 -0400

The stock options have an exercise price of $8.88 per share, which is equal to the closing price of the company’s common stock on September 1, 2026. Each stock option has a ten-year term

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: STEMPOINT CAPITAL LP

Fri, 14 Aug 2026 12:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26927526.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: STEMPOINT CAPITAL LP

Fri, 14 Aug 2026 12:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26927526.html

Xilio Therapeutics, Inc. (XLO) Tops Q2 EPS by 25c

Wed, 12 Aug 2026 07:48:41 -0400

Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q2 EPS of ($0.33), $0.25 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $7.27 million.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.

Form S-8 Xilio Therapeutics, Inc.

Wed, 12 Aug 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260812/26909013.html

Form S-8 Xilio Therapeutics, Inc.

Wed, 12 Aug 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260812/26909013.html

Form 10-Q Xilio Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26908991.html

Form 10-Q Xilio Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26908991.html

Form 8-K Xilio Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260812/26908975.html

Form 8-K Xilio Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260812/26908975.html

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Wed, 12 Aug 2026 07:30:00 -0400

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027

Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies

WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Wed, 12 Aug 2026 07:30:00 -0400

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies